ChromaDex Chief Scientific Advisor, Charles Brenner, PhD, to discuss nicotinamide riboside in educational session IRVINE, Calif., May 29, 2018 -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people...
ChromaDex Appoints Nobel Laureate, Professor Sir John Walker, to the Scientific Advisory Board
World-Renowned British Chemist to Assist in Uncovering New Applications for Nicotinamide Riboside and Mitochondrial Health IRVINE, Calif., May 14, 2018 -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way...
ChromaDex Corporation Reports First Quarter 2018 Financial Results
- First Quarter 2018 Net Revenues Increased by 95% to $6.6 Million - IRVINE, Calif., May 10, 2018 -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to improving the way people age, announced today first quarter 2018...
ChromaDex Sets First Quarter 2018 Financial Results on Thursday, May 10, 2018
IRVINE, Calif., May 03, 2018 -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, will report financial results for the first quarter of 2018 on Thurs., May 10, 2018. The Company's financial...
ChromaDex Remains Confident Amidst Inter Partes Review (IPR) Procedural Changes
SAS Supreme Court decision regarding challenged claims in an IPR has no effect on U.S. Patent 8,197,807 IRVINE, Calif., May 01, 2018 -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age,...
ChromaDex Appoints Frank Jaksch As Executive Chairman, Rob Fried as Chief Executive Officer and Kurt Gustafson as Lead Director
New Management Structure Further Fuels Strategic Evolution into Consumer-Focused Integrated Nutraceutical Company IRVINE, Calif., April 23, 2018 -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people...
TRU NIAGEN® to be featured at the American Academy of Anti-Aging Medicine Spring Congress
Keynote Speaker, Dr. Rudolph E. Tanzi, will sign copies of his new book, "The Healing Self," at the TRU NIAGEN booth IRVINE, Calif., April 05, 2018 -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way...
New Published Clinical Trial Confirms NIAGEN® Supplementation Raised Nicotinamide Adenine Dinucleotide (NAD) Levels and Potentially Improves Blood Pressure and Cardiovascular Health
Findings from the University of Colorado, Boulder Study Suggest Future Studies Should Focus on the Therapeutic Potential for Blood Pressure and Vascular Health IRVINE, Calif., March 29, 2018 -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical...
ChromaDex Corporation Reports 2017 Financial Results
Fourth Quarter 2017 Net Revenues Increased by 69% to $7.5 Million IRVINE, Calif., March 08, 2018 -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to improving the way people age, announced today fourth quarter and full...
ChromaDex to Present at the 30th Annual ROTH Conference on March 12, 2018
IRVINE, Calif., March 06, 2018 -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way people age, has been invited to present at the 30th Annual ROTH Capital Partners...